FK506 and rapamycin are immunosuppressants that inhibit signalling cascades required for T-cell activation, yet both are natural products of Streptomyces that live in the soil. FK506 and rapamycin also have potent antimicrobial activity against yeast and pathogenic fungi, suggesting a natural role in inhibiting growth of competing micro-organisms. The immunosuppressive and antimicrobial activities of FK506 and rapamycin are mediated by binding to the FKBPl2 prolyl isomerase and the resulting FKBPl21FK506 and FKBP12/rapamycin complexes inhibit conserved protein targets, either the phosphatase calcineurin or the TOR (target of rapamycin) kinases, respectively.
INTRODUCTION
A variety of micro-organisms produce secondary metabolites or natural products, many of which exhibit toxic activity against different cells and organisms (Chadwick & Whelan, 1992) . These natural products have proved to be a valuable resource to identify drugs with specific physiological effects in animals. For example, the immunosuppressants FK.506 (tacrolimus), Abbreviation: TOR, target of rapamycin.
FK.520 (ascomycin, an active FK.506 derivative in which the C21 ally1 group is replaced by an ethyl group) and rapamycin (sirolimus) were originally identified by screening random soil samples for biological activities and were later found to be products of Streptomyces sp., ' Streptomyces hygroscopicus subsp. ascomyceticus ' and Streptomyces hygroscopicus, actinomycetes that live in the soil (Baker et al., 1978; Hatanaka et al., 1988a, b ; Kino et al., 1987; Morisaki & Arai, 1992; Sehgal et al., 1975; Singh et al., 1979; Vezina et al., 1975) . FK506 is now in widespread use as an immunosuppressant to prevent and treat graft rejection in solid organ transplant 0002-3426 0 1999 SGM recipients id for graft-vs. host disease in bone marrow transplant recipients. RapLimycin is in late phase 111 clinical trials for similar purposes (Cardenas et al., 19953) .
Considcrablc progress has been made in delineating the biosynthetic pathways by which Streptomyces elaborates these complex macrolide compounds. A cluster of enzymes has been identified which mediates rapamycin biosynthesis (Schwecke et al., 199.5 ) and mutational iipproachcs have been employed to define the pathways involved in both rapamycin (Khaw et al., 1998 ; Lomovskaya et al., 1997) and FKS06 biosynthesis (Motamedi et al., 1997) . Finally, numerous analogues of these compounds have been produced by biotransformation, altered growth medium conditions and semisynthetic organic chemistry (Khaw et al., 1998 ; Luengo et al., 1995; Nishida et al., 199S) , and these analogues might have novel or improved biological activities.
FK.506 and rapamycin suppress the immune system by inhibiting signal transduction cascades required for T-1 y m p h oc y t e iic t i v:~ t i o n d u ring ti ssue re j ec t ion. I n mammals, the activities o f FKS06 and rapamycin are relatively specific for lymphocytes, with only limited effects observed in other cells and tissues. This cell type specificity of FKS06 and rapamycin raises a paradox: how did soil micro-organisms evolve to produce such Tcell-specific agents when they rarely, if ever, encounter large animals ? Moreover, suppressing the immune system is not a particularly effective o r rapid means of doing harm to a large animal and many microbial toxins directed against mammals target the nervous system. Hence, immunosuppression by FK.506 or rapamycin is not likely to be a normal role in nature. In fact, FKSO6, cyclosporin A and rapamycin exhibit antimicrobial activity against a variety of different bacteria, yeasts, parasites and fungi and might therefore function to inhibit the growth of competing micro-organisms (High, 1994; McCabc et al., 1986; Odom et ul., 1997a, b ; Wong et a/., 1998) .
Recent studies reveal that the molecular mechanisms of the immunosuppressive and antimicrobial effects of FKS06 and rapamycin are remarkably similar and involve inhibition of highly conserved target proteins (Abraham & Wiederrecht, 1996; Heitman et al., 1992; Schreiber & Crabtree, 1992) . Both drugs are hydrophobic and enter the cell by diffusion. Next they bind to a highly conserved intracellular protein, FKBP12, which is conserved from unicellular eukaryotes such as Sacchuromyces cerevisiae to man. FKBP12 is an enzyme that catalyses cis-trans peptidyl prolyl isomerization, a rate-limiting step during protein refolding in vitro. Both FKS06 and rapamycin bind to the FKBP 12 active site and inhibit activity, but this is not the mechanism by which these agents are toxic. Instead, the protein/drug complexes are the active in vivo agents. For example, yeast mutants lacking FKBP12 are viable and resistant to FKS06 and rapamycin (Breuder et al., 1994; Heitman et al., 1991a, b; Hemenway et al., 1995; Parent et al., 1993) ~ ~ ~~ _ _ ~ and increasing FKBP 12 protein levels in mammalian cells by transfection results in increased drug sensitivity (Bram et a/., 1993) .
T h e targets of FKBP12/drug complexes are elements of signal transduction pathways conserved from yeast to man. T h e target of the FKBP12/FKS06 complex was first identified as calcineurin by drug affinity chromatography of mammalian cell extracts (Liu et al., 1991) . Subsequent studies revealed that calcineurin was the conserved target of FKSO6 in yeast (Breuder et al., 1994; Foor et al., 1992; Parent et a/., 1993) . Calcineurin is a calcium/calmodulin activated protein phosphatase that plays a central role in signal transduction from the T-cell receptor to regulate T-cell activation and plays diverse roles in yeast involving gene regulation and cation homeostasis. T h e target of the FKBP 12/rapamycin complex was first identified by genetic and molecular studies in yeast as the T O R (target of rapamycin) kinase homologues (Cafferkey et al., 1993; Heitman et al., 1991a, b; Helliwell et al., 1994; Kunz et al., 1993) and the mammalian target of rapamycin ( m T O R , RAFT1, FRAP) shares -SO '/o sequence identity with yeast T O R
proteins (Brown et al., 1994; Chiu et al., 1994; Sabatini et al., 1994; Sabers et al., 1995) . T O R kinase has been functionally conserved from yeast to man and plays a central role in regulating cell cycle progression and translation in lymphocytes in response to growth factors and, in yeast, in response to nutrients (Alarcon et al., 1996; Barbet et al., 1996; Brunn et al., 1997;  di Como & Arndt, 1996) .
Taken together, these observations suggest that Streptomyces may have originally evolved the ability to synthesize and secrete FKS06 and rapamycin as antimicrobial agents to inhibit the growth of competing micro-organisms in the soil. Such a role would be analogous to that attributed to antibiotics produced by fungi. Because the proteins that FKS06 and rapamycin target have been highly conserved during evolution, their original activity against yeast and fungal targets could have been maintained against the mammalian homologues. Here we have tested this hypothesis and present evidence that Streptomyces spp. indeed secrete potent toxins that inhibit the growth of competing cells of the ascomycetous yeast Saccharomyces cerevisiae and also of the very distantly related basidiomycetous pathogenic fungus Cvyptorocctls neoformans.
METHODS

Media.
Yeast YPD medium was prepared as described by Sherman (1991 Cruz et al. (1999) scribed morphological characteristics. For example, S. hygroscopicus formed colonies that invaded the agar, were quite hydrophobic and formed colonies of two distinct types, either powdery whitish grey or dark black . The isogenic pair of rapamycin-producing (ATCC 29253) and rapamycin-deficient (WHM1651) strains of S. hygroscopicus were kindly provided by Dr C. Hutchinson, University of Wisconsin, Madison, WI, USA (Lomovskaya et al., 1997) . The isogenic pair of FK506-producing (MA6548) and FK506-reduced production strains of Streptomyces sp. were provided by Dr Haideh Motamedi, Merck, Rahway, NJ, USA (Motamedi et al., 1997) .
Saccharomyces cerevisiae and C. neoformans strains are listed in Table 1 and most have been described previously (Breuder et al., 1994; Cardenas et al., 1995b; Heitman et al., 1991a, b; James et al., 1996; Odom et al., 1997a, b) . Strain SMY87-4 is an isogenic derivative of the two-hybrid host strain PJ69-4A (James et al., 1996) in which the FKBP12-encoding gene, FPRl, has been disrupted by fprl : : hisG-URA3-hisG and then selected for fprl : : hisC recombinants by selection for growth on 5-fluoroorotic acid (5-FOA) medium.
Growth inhibition assays.
Saccharomyces cerevisiae or C. neoformans strains were cultured in YPD liquid medium and -lo' cells were resuspended in 3 ml top agar (0.7% Bacto agar in water), which was poured onto the surface of YPD medium (90 or 140 mm plates) and allowed to solidify. Discs containing either ' S. ascomyceticus ' or S. hygroscopicus were prepared by incubating a lawn of cells on sporulation agar at 24 "C. Plugs of agar with overlaying colonies, mycelium and spores were excised with the larger end of a sterile Pasteur pipette and placed (colony side down) on the surface of medium containing yeast or fungal cells. Co-cultures were incubated for 48 h at 30 or 37 "C. Growth inhibition was quantified by measuring the distance from the edge of the disc to the zone of growth (the radius of growth inhibition).
Two-hybrid interactions.
Plasmids expressing the GAL4(BD)/yeast FKBP12, GAL4(AD)/yeast calcineurin A, GAL4(BD)/C. neoforrnans TOR1 FKBP12/rapamycin-binding domain and GAL4(AD)/C. neofoimans FKBP12 have been described (Cardenas et al., , 1995b Cruz et al., 1999) . A two-hybrid host strain, SMY87-4 (see Table l ) , was co-transformed with control plasmids, with plasmids expressing GAL4(BD)/yeast FKBP12 and wild-type and mutant GAL4(AD) /yeast calcineurin fusions, and with plasmids expressing wild-type and mutant GAL4(BD) /TOR1 and GAL4(AD)/FKBP12 fusions. Cells were resuspended in top agar on the surface of synthetic medium lacking tryptophan, leucine and adenine, and were then overlaid with inverted agar discs bearing 'S. ascomyceticus ' or S. hygroscopicus. Control discs contained FK506 (1 p g ) , rapamycin (1 pg) or no drug. Cells were incubated for 3-5 d at 30 "C. Colony formation is indicative of GAL4-dependent expression of the GAL-ADE2
reporter gene fusion as a consequence of FKBP12/ligand/ calcineurin or FKBP12/ligand/TOR interactions.
RESULTS
Streptomyces in hi bits Saccharomyces cerevisiae growth via FKBP12-dependent inhibition of calcineurin
To determine if FK506 a n d FK520-producing Streptomyces spp. secrete toxins that inhibit the growth of competing micro-organisms, we utilized a series of mutants of the yeast Saccharomyces cerevisiae that a r e sensitive o r resistant t o FK506 a n d FK.520 by defined genetic mutations. M a n y laboratory strains of yeast are myces cermisiae have been identified in which calcineurin is essential for viability and these strains are sensitive to growth inhibition by FK.506 and FK.520 a t a MIC of -1 pg ml-' (Breuder et al., 1994; Douglas et al., 1994; Hemenway et al., 199.5; Parent et al., 1993 (Breuder et al., 1994; Cardenas et al., 199.5 
b) .
To establish whether ' S. ascomyceticus ' secretes the toxin FK.520, the FK.506-and FK.520-sensitive yeast strain TB23 was cultured in the presence of 'S. ascomvceticz4s '. For these experiments, yeast cells were resuspended in molten top agar and overlaid on rich YPD medium. Once the top agar had solidified, an agar disc containing 'S. ascomyceticus' was placed on the surface. Growth of the FK.520-sensitive yeast strain TB23 was potently inhibited by ' S. ascomyceticus ', resulting in a zone of inhibition with a radius of 1 cm (Fig. 1, upper discs) . T h e major component of this toxic activity can be identified as FK.520, because isogenic FK.520-resistant mutant strains lacking FKBP12 ( f p r l ) or expressing a dominant FK.520-resistant calcineurin mutant (CMPZ-I) were relatively resistant to growth inhibition by the 'S. ascomyceticus' toxin (Fig. 1) . In these cases, smaller zones of growth inhibition with radii of 0.35 cm were observed. Based on these observations, we conclude that ' S. ascomyceticus ' secretes FK520 at a level sufficient to inhibit the growth of
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-~ ~ Similar results were obtained with an isogenic pair of Streptomyces strains, one that produces FK.506 (MA6.548) and the second which has a mutation in the FK.506 biosynthetic machinery and produces reduced levels of FK.506 (Motamedi et al., 1997) . As shown in Fig. 1 , the wild-type FK.506-producing strain inhibited the growth of the FK.506-sensitive yeast strain TB23 to yield a modest zone of inhibition with a radius of 0.24 cm, whereas the mutated Streptomyces strain that produces a reduced level of FK.506 did not inhibit growth (Fig. 1) . Yeast mutants lacking FKBP12 ( f p r l ) or expressing an FK.506-resistant calcineurin mutant (CMP2-1) were resistant to the toxic activity secreted by the wild-type Streptomyces strain (Fig. 1) . A control disc containing FK.506 inhibited the growth of the wild-type yeast strain (0.67 cm radius zone of inhibition) but not of either FK.506-resistant mutant yeast strain (Fig. 1 ).
S. hygroscopicus in hi bits Saccharomyces cerevisiae growth via FKBP12-dependent inhibition of TOR
We performed analogous experiments to test if the rapamycin-producing actinomycete S. hygroscopicus also secretes toxins that inhibit yeast growth. Rapamycin potently inhibits the growth of all laboratory yeast strains that have been tested, with an M I C of -2.5-100 ng ml-' (Heitman et al., 1991a) . Yeast mutants that are resistant to rapamycin either lack the rapamycin drug-binding protein FKBP12 ( f p r l ) o r express mutant forms of the FKBP12/rapamycin target proteins, the TOR kinase homologues, which do not bind the FKBP12/rapamycin complex as a consequence of mutations in the FKBP12/rapamycin-binding domain on TOR (Cafferkey et al., 1993; Heitman et al., 1991a; Helliwell et al., 1994; Lorenz & Heitman, 1995; Zheng et a/., 1995) .
S . hygroscopicus secretes a toxin that potently inhibits
the growth of the wild-type, rapamycin-sensitive yeast strain JK9-3d, resulting in a zone of inhibition with a radius of 1.56 cm (Fig. 2, upper Streptomyces strain MA6548 or an isogenic mutant strain that produces reduced levels of FK506. In previous studies, we found that growth of C. neoformans is resistant to the calcineurin inhibitor FK506 at 24 "C but markedly sensitive at 37 "C (Odom et al., 1997a, b) . Correspondingly, C. neoformans mutants lacking calcineurin are viable at 24 "C but not at 37 "C; hence, calcineurin is essential for growth at elevated temperatures in this organism (Odom et al., 1997a) .
In accordance with these observations, a toxin secreted by Streptomyces strain MA6548 potently inhibited C. neoformans growth at 37 "C (halo radius 1.23 cm) but not at 30 "C (Fig. 3, upper left disc) . Moreover, the FK.506-resistant FKBP12 mutant strain (frrl-3, C21F3) and a dominant FK.506-resistant, rapamycin-sensitive mutant strain that is likely to harbour a calcineurin mutation (FKRl -1, C21F2) were completely resistant to growth inhibition by Streptomyces sp. (Fig. 3) . In comparison, the zone of inhibition of the wild-type strain was reduced to 0.68 cm with the Streptomyces mutant strain that produces reduced FK506 and this strain did not inhibit growth of the FK.506-resistant C. neoformans strains (Fig. 3, upper right disc) . Finally, a control disc containing FK.506 potently inhibited the growth of wild-type cells at 37 "C but not at 30 "C, and did not inhibit growth of the frrZ or F K R I -2 FK506-resistant mutant strains (Fig. 3, lower The S. hygroscopicus wild-type strain produces a toxin that potently inhibits the growth of the wild-type C. neoforrnans strain JEC21 (zone of inhibition radius 1.45 cm) (Fig. 4, upper left disc) . In comparison, the compared to the isogenic wild-type strain JEC2l (Fig.  4) . Similarly, an isogenic mutant strain expressing a T O R 1 mutant protein that no longer binds FKBP12/ rapamycin (Cruz eta/., 1999) was also relatively resistant to the S. hygroscopicus toxin, with a zone of inhibition with a radius of 0.75 cm (Fig. 4) . In accordance with these findings, the zone of growth inhibition with the Streptomyces WHM16.51 mutant strain that does not produce rapamycin was reduced to 0.75 cm in both the rapamycin-sensitive wild-type strain JEC21 and the rapamycin-resistant frrl and tor1 -1 mutant strains (Fig. 4, upper right disc) . Finally, a control disc containing rapamycin potently inhibited the growth of -~_ _ the wild-type strain (zone of inhibition radius 1.45 cm), whereas the f r y 1 mutant strain was completely resistant to rapamycin and the torl-l mutant strain was largely resistant to rapamycin (Fig. 4, lower disc) . Taken together, these observations indicate that S. hygroscopicus produces both rapamycin and a second toxin with a different mechanism of action (Fig. 4) Cells were plated in top agar on synthetic medium lacking leucine and tryptophan (to select for the plasmids) and also lacking adenine (as a measure o f expression of the GAL-ADE2 reporter gene).
S. hygroscopicus inhibits C. neoforrnans growth via FKBP12-dependent inhibition of TOR
T h e cells were then overlaid with inverted agar discs bearing ' S. ascomyceticiis ' or a disc containing FKS06. A halo of colonies was observed surrounding both the disc bearing ' S. ascornyceticus ' and the control disc containing FK506, but not around a control disc lacking FKS06 or a n agar disc bearing S. hygroscopicus, which secretes rapamycin but not FKS20 (Fig. 5a ). T h e presence of growth indicates the formation of a GAL4/FKBP12/ 1 ig a 11 d /cii 1 c i ne ci r i n / G A L4 co m p 1 ex t h at then activates transcription o f the GAZ,-ADE2 reporter gene to support growth in medium lacking adenine. In contrast, no growth was observed when a mutation (W388C, CMP2-1) that prevents FKBP12/FK506 binding was introduced into the GAL4/calcineurin A fusion protein (Fig. Sa,  CNA") . Finally, the finding that a zone of inhibition surrounded the disc of 'S. ascomycetici.is', but not the control disc with FK506 alone, indicates that ' S. ascomyceticiis ' secretes FKS20 and an additional toxin. In summary, these observations support the conclusion thzit ' S. ~rscomyceticzrs ' secretes sufficient FKS20 to form FKBP 12/FKS20/calcincurin complexes in competing yens t cc 1 1 s .
S. hygroscopicus toxin mediates cryptococcal FKBPl2/TOR interaction
Analogous experiments were performed using the yeast two-hybrid system t o test if S. hygroscopicus secretes rapamycin and promotes formation of an FKBP12/ rapaniycin/TOR complex. In this case, the yeast twohybrid strain was co-transformed with plasmids that express GAL4(BD)/TOR and GAL4(AD)/FKBP12 fusion proteins. In addition, to render growth of this strain resistant to rapamycin, a third plasmid was introduced that expresses a dominant, rapamycinresistant allele of the yeast T O R 1 protein. Again, growth was readily apparent surrounding the agar disc bearing S. hygroscopiciis and around a disc bearing rapamycin, but not around ii control disc or an agar disc bearing 'S. miomyceticiis' (Fig. 5b) . In this assay, growth indicates formiition of an FKBP12/rapamycin/TOR complex and GAL4-dependent expression of the GAL-ADE2 reporter gene. I n contrast, no growth was observed when a mutation that prevents FKBP12/rapamycin binding to TOR was introduced into the GAL4(BD)/TOR fusion protein (Fig. 5B, TOR 
DISCUSSION
Streptomyces and a variety of other micro-organisms produce a vast array of natural products, many of which are antibiotics, toxins and important pharmaceuticals.
Here we present evidence that Streptomyces spp. produce the immunosuppressants FK506, FK520 and rapamycin as antimicrobial agents to inhibit the growth of competing micro-organisms (Fig. 6) . (Fig. 6) .
The mechanisms by which Streptomyces produce these antifungal agents provides further evidence that these compounds may have evolved early and for a specific purpose. FK506 and rapamycin are members of the macrolide family of compounds, which are synthesized by polyketide synthases. In the case of rapamycin, a large array of related biosynthetic enzymes have been characterized that catalyse the sequential steps in the synthesis of the macrolide ring (Aparicio et al., 1996; Molnar et al., 1996; Schwecke et al., 1995) . A related series of enzymes is involved in the biosynthesis of FK506 and FK520 (Motamedi et al., 1996; Nielsen et al., 1991) . In both cases, a large, complicated series of genes is required to synthesize the natural product. Other macrolides, such as the antibiotic erythromycin, are synthesized by similar, related enzyme clusters (Cortes et al., 1990; Donadio et al., 1991; Katz, 1997) . The diversity of compounds produced by related means suggests that these enzymes may have evolved quite early, perhaps prior to the evolution of multicellular eukaryotes and consistent with a role as antimicrobial agents. Many other members of the macrolide family, including erythromycin and streptomycin, are wellknown antibiotics, again suggesting that the role of other members of this family of natural products could serve to inhibit the growth of competing microorganisms. The great complexity of the biosynthetic machinery for these natural products requires that the producing organism invests a great deal of energy in their synthesis, which would again be consistent with a role in growth competition. An alternative hypothesis is that the natural products FK.506 and rapamycin might play a signalling role as pheromones, but no evidence to support such a role has as yet been adduced. A general question that applies to all micro-organisms that make toxins is how the producing organism protects itself from potential suicide. In some cases, such as colicin production in bacteria, the host cell produces an immunity protein that counteracts the lethal action of the toxin. In the case of Streptomyces that produce FK506 and rapamycin, these organisms have been found to express an FKBP12 homologue that binds FK520 and rapamycin with high affinity (Pahl & Keller, 1992) . On the other hand, both S. hygroscopicus and ' S . ascomyceticus' were found to be resistant to both FK520 and rapamycin (Pahl & Keller, 1992) . One plausible hypothesis is that these bacteria lack the calcineurin and T O R protein targets of FKBP12/drug complexes. Alternatively, calcineurin and TOR homologues might be present but not required for vegetative growth, as is the case with calcineurin in wild-type Saccharomyces cereuisiae strains and may be the case for T O R in Schizosaccharomyces pombe in which vegetative growth is not sensitive to rapamycin (Weisman et al., 1997 The targets of these agents, the FKBP12 prolyl isomerase, the phosphatase calcineurin and the T O R kinase homologues, are highly conserved from yeast to man with -50% sequence identity despite -1 billion years of evolution. In the case of calcineurin and TOR, one hypothesis is that these proteins play important signal transduction roles involving other conserved signalling molecules and that this, in part, has constrained their evolution. The case of FKBP12 is much more mysterious given that its stable interactions with calcineurin and T O R occur only when FK506 or rapamycin are present. Our previous findings have suggested that these proteins might normally interact under some physiological conditions (see . In summary, natural products that evolved to target yeast and fungal growth can have quite specific effects in multicellular eukaryotes by targeting conserved target proteins. Our studies underscore the highly conserved nature of life and the power of studies on natural product toxins, both as probes of cell function and as a source of valuable pharmaceuticals. These studies may also enable mutagenic approaches to study FK506-and rapamycinproducing organisms and enzymes, and their specificity. For example, our approaches could be readily adapted to screen for mutant bacteria that make toxins that act via FKBP12 but not on calcineurin or TOR. Alterations in culture conditions and biotransformation approaches have been found to result in the production of drug analogues (Khaw et al., 1998; Nishida et al., 1995) and these could be readily screened for activity against novel targets using the approaches described here. Finally, novel FKBP12-binding ligands may already exist in nature and in fact two classes of novel FKBP12-binding ligands, meridamycin and the antascomicins, have recently been described (Fehr et al., 1996; Salituro et al., 1995) . Although the biological properties of these novel agents remain to be explored, our studies suggest that one role might be as novel antimicrobial agents.
